Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of ETV, TDF, and TAF in Chronic Hepatitis B
NCT04195074Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (3 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Rate of renal function decline at 144 weeks and Rate of hypercalcemia at 144 weeks. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04195074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195074.